LSE:HSBA
LSE:HSBABanks

Assessing HSBC (LSE:HSBA) Valuation After Strong Revenue Growth And Multi‑Year Shareholder Returns

Why HSBC Holdings (LSE:HSBA) is on investors’ radar now HSBC Holdings (LSE:HSBA) has caught investor attention after delivering annual revenue of £57,976m and net income of £16,580m, prompting a closer look at how its current valuation lines up with its fundamentals. See our latest analysis for HSBC Holdings. HSBC Holdings’ share price has been firming up, with a 1-day share price return of 1.21% and a 90-day share price return of 20.88%. Its 1-year total shareholder return of 60.32% and...
LSE:RIO
LSE:RIOMetals and Mining

Rio Tinto AWS Copper Deal Highlights Opportunity In Low Carbon Growth

Rio Tinto Group and Amazon Web Services have agreed that AWS will be the first customer for Rio Tinto's low carbon copper produced using its Nuton bioleaching technology. The deal introduces Nuton copper into commercial use, with AWS planning to use the material in support of its sustainability goals in cloud and data center operations. Rio Tinto will also use AWS tools to help refine and scale the Nuton bioleaching process. For investors watching Rio Tinto Group (LSE:RIO), this news sits...
LSE:LLOY
LSE:LLOYBanks

Lloyds Banking Group (LSE:LLOY) Valuation Check After Strong Recent Share Price Returns

Why Lloyds Banking Group is on investor watchlists today Lloyds Banking Group (LSE:LLOY) has drawn fresh interest after recent share price gains over the month and past 3 months, prompting investors to reassess how its current valuation lines up with fundamentals. See our latest analysis for Lloyds Banking Group. Recent trading has been strong, with a 1 day share price return of 3.32% and a 90 day share price return of 22.31%. The 1 year total shareholder return of 83.53% and 5 year total...
LSE:GLEN
LSE:GLENMetals and Mining

Glencore Lithium Deal Deepens Battery Supply Role In UK And Europe

Glencore subsidiary agrees a five year lithium hydroxide offtake deal with Alkemy Capital Investments' planned Teesside refinery in the UK. The agreement secures battery grade lithium chemicals supply for Glencore, targeting customers across the UK and wider European battery sector. The move expands Glencore's role in the battery raw materials chain as demand grows for materials linked to EVs and energy storage. For investors watching LSE:GLEN, this new offtake deal comes with the shares...
LSE:FRES
LSE:FRESMetals and Mining

Fresnillo Guidance Cut Puts Focus On Valuation And Volatile Share Price

Fresnillo (LSE:FRES) has cut its 2025 production guidance after reporting lower silver and gold output. The company links the change to operational adjustments at its Fresnillo mine that are affecting ore processing and grade. The updated guidance reflects a response to current mine performance rather than external market factors. The move comes with Fresnillo shares at around £37.02, after a sharp 11.2% decline over the past week but a gain of 11.0% over the past month. Over longer...
LSE:BARC
LSE:BARCBanks

Assessing Barclays (LSE:BARC) Valuation After Recent Share Price Momentum And Tech Investment Focus

With no single headline event driving Barclays (LSE:BARC) today, the stock’s recent performance and fundamentals take center stage. This includes a £4.86 last close and £26.02b in reported revenue. See our latest analysis for Barclays. At a £4.862 share price, Barclays has seen momentum build recently, with a 19.46% 3 month share price return and a 68.05% 1 year total shareholder return that underline how sentiment around its risk and growth profile has shifted. If Barclays has caught your...
LSE:AZN
LSE:AZNPharmaceuticals

AstraZeneca’s China Bet Recasts Growth Story Around Obesity And Diabetes

AstraZeneca (LSE:AZN) has announced a $15b investment in China focused on R&D and manufacturing. The plan includes building end to end cell therapy capabilities and expanding local partnerships with Chinese and UK institutions. The company has also agreed a new partnership with CSPC Pharmaceuticals to develop obesity and diabetes treatments using AI driven discovery and once monthly dosing platforms. AstraZeneca, a global biopharmaceutical group focused on oncology, cardiovascular, renal,...